Clinical trials: Placebo Group
Irritable Colon, Irritable Bowel Syndrome (IBS)
Study Of Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy
The purpose of this study is to compare the safety and effectiveness of different doses of an investigational medication in women with severe diarrhea-predominant Irritable Bowel Syndrome (IBS) who have failed conventional…
- Trial name
- NCT00067561
- Testing
- Alosetron
- Where
- 178 sites in United States, Australia
- Volunteers
- 702 people
- Sponsor
- GlaxoSmithKline
Healthy Subjects (HS)
To Evaluate the Effect of Bacillus Coagulans Based Product in Gut Health and Immunomodulatory Effect in Healthy Adults
This randomized, double-blind, placebo-controlled clinical trial is designed to evaluate the effects of a Bacillus coagulans-based probiotic product on gut health, immunological parameters, and overall tolerability in healthy…
- Trial name
- NCT07377994
- Testing
- Probiotic (Bacillus Coagulans)
- Where
- India
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Bioagile Therapeutics Pvt. Ltd.
Healthy
Single Rising Oral Doses of BI 10773 in Healthy Male Volunteers
Study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 10773 administered to healthy Japanese male subjects with single rising oral doses (1, 5, 10, 25, and 100 mg).
- Trial name
- NCT02182453
- Testing
- BI 10773 - single rising dose
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Ulcerative Colitis
A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis
The purpose of this study is to evaluate efficacy and safety of PF-06826647 in moderate to severe ulcerative colitis
- Trial name
- NCT04209556
- Testing
- PF-06826647 100 mg QD, PF-06826647 300 mg QD, PF-06826647 600 mg QD
- Where
- 24 sites in United States
- Sponsor
- Pfizer
Gastrointestinal Diseases
Efficacy and Tolerability of Buscopan Plus in Painful Gastric or Intestinal Spasms
Study to evaluate efficacy and tolerability of Buscopan® plus versus Buscopan®, paracetamol, and placebo in patients with painful gastric or intestinal spasms.
- Trial name
- NCT02229786
- Testing
- Buscopan® plus, Buscopan®, Paracetamol
- Volunteers
- 1,637 people
- Sponsor
- Boehringer Ingelheim
Relapsing-Remitting Multiple Sclerosis
CLARITY Extension Study
The purpose of this extension trial was to further evaluate the safety and tolerability of oral cladribine in subjects who have previously completed treatment within Trial 25643 (CLARITY).
- Trial name
- NCT00641537
- Testing
- Cladribine
- Where
- 116 sites in United States, Australia and 29 more
- Volunteers
- 867 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Cystic Fibrosis, Bronchiectasis
A Study to Test How Well BI 1291583 is Tolerated by People With Cystic Fibrosis Bronchiectasis (Clairafly™)
This study is open to adults aged 18 years and older with cystic fibrosis bronchiectasis. The purpose of this study is to find out whether a medicine called BI 1291583 is tolerated by people with cystic fibrosis bronchiectasis.
- Trial name
- NCT05865886
- Testing
- BI 1291583
- Where
- 24 sites in United States, Belgium and 5 more
- Volunteers
- 22 people
- Sponsor
- Boehringer Ingelheim
Restless Legs Syndrome, End-Stage Renal Disease
A Sleep Laboratory Study to Investigate the Safety and Efficacy of the Rotigotine Skin Patch in Subjects With Restless Legs Syndrome and End-Stage Renal Disease Requiring Hemodialysis
This is a sleep laboratory study to evaluate the efficacy and safety of Rotigotine in subjects with Restless Legs Syndrome and End-Stage Renal Disease requiring hemodialysis.
- Trial name
- NCT01537042
- Testing
- Rotigotine
- Where
- 15 sites in United States, Austria and 4 more
- Volunteers
- 30 people
- Sponsor
- UCB BIOSCIENCES GmbH
COPD (Chronic Obstructive Pulmonary Disease)
A Study to Investigate the Biomarkers of Hemay005 in Adult Participants With Moderate to Severe COPD
A Multicenter, Randomized, Double-blind, Single-dummy, positive drug and placebo-controlled, Parallel Group, Phase 2a Study to Evaluate the Efficacy and Safety of Hemay005 in Adults with Moderate to Severe Chronic Obstructive…
- Trial name
- NCT07314242
- Testing
- Hemay005 tablets, Roflumilast Oral Tablet
- Where
- 2 sites in China
- Volunteers
- 120 people
- Sponsor
- Ganzhou Hemay Pharmaceutical Co., Ltd
Osteoporosis, Postmenopausal
Risedronate in the Prevention of Osteoporosis in Postmenopausal Women
Primary Objective: To demonstrate that risedronate 35-mg once weekly is more efficacious than placebo in increasing or maintaining bone mineral density (BMD) of the lumbar spine after 1 year of treatment in women who are…
- Trial name
- NCT00402441
- Testing
- Risedronate (HMR4003)
- Where
- United States
- Volunteers
- 260 people
- Sponsor
- Sanofi
Crohn's Disease
An Efficacy and Safety Study of Omega-3 Free Fatty Acids (Epanova™) for the Maintenance of Symptomatic Remission in Subjects With Crohn's Disease
The purpose of this study is to see if Epanova™ is able to maintain the symptomatic remission in subjects with Crohn's Disease who are responding to steroid induction therapy.
- Trial name
- NCT00074542
- Testing
- Epanova™ (Omega-3 Free Fatty Acids)
- Where
- 31 sites in United States, Canada
- Volunteers
- 364 people
- Sponsor
- Tillotts Pharma AG
Amyotrophic Lateral Sclerosis
Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis
The alteration of iron metabolism is reported in animal models of amyotrophic lateral sclerosis (ALS) as well as in sporadic and genetic forms (SOD1 and C9orf72) of ALS.
- Trial name
- FAIR-ALS II (NCT03293069)
- Testing
- Deferiprone
- Where
- 15 sites in France
- Volunteers
- 372 people
- Sponsor
- University Hospital, Lille
Non-Segmental Vitiligo
A Study to Learn How Safe ACT-777991 is and How Well it Works in Adults With Non-segmental Vitiligo
The purpose of this clinical trial is to learn how well ACT-777991 works, how safe it is and how well it is tolerated by adults with non-segmental vitiligo.
- Trial name
- NCT07667569
- Testing
- ACT-777991
- Where
- 5 sites in United States, Poland
- Volunteers
- 30 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Restless Legs Syndrome
Efficacy and Safety Study of Topiramate to Treat Restless Legs Syndrome
This study is intended to determine whether topiramate is an efficacious and safe treatment for restless legs syndrome.
- Trial name
- NCT00200941
- Testing
- Topiramate
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Neurocare
Giant Cell Arteritis (GCA)
Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)
This is a phase III study of efficacy and safety of secukinumab versus placebo, in combination with glucocorticoid taper regimen, in patients with giant cell arteritis (GCA)
- Trial name
- GCAptAIN (NCT04930094)
- Testing
- Secukinumab 300 mg, Secukinumab 150 mg
- Where
- 104 sites in United States, Argentina and 25 more
- Volunteers
- 354 people
- Sponsor
- Novartis Pharmaceuticals
Schizophrenia
Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants With Schizophrenia Experiencing Inadequate Response to Ongoing Antipsychotic Treatment
This study will be conducted to evaluate the efficacy, safety, and tolerability of GWP42003-P versus placebo in participants with schizophrenia experiencing inadequate response to ongoing antipsychotic treatment.
- Trial name
- NCT04421456
- Testing
- GWP42003-P
- Where
- 39 sites in United States, Poland and 2 more
- Volunteers
- 95 people
- Sponsor
- Jazz Pharmaceuticals
Pediatric Migraine
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in the acute treatment of moderate or severe migraine in children and adolescents.
- Trial name
- NCT04649242
- Testing
- Rimegepant/BHV3000
- Where
- 246 sites in United States, Canada and 7 more
- Volunteers
- 2,100 people
- Sponsor
- Pfizer
Migraine
To Evaluate the Blockade of CGRP in Preventing PACAP-38 Induced Migraine-like Attacks With AMG 334 in Migraine Patients
Phase I, Randomized, Parallel-group, Double-Blind, Placebo-Controlled, Single Dose Study to Evaluate the Blockade of CGRP Receptor by AMG 334 in Preventing PACAP-38 Induced Migraine-like Attacks in Migraine Patients.
- Trial name
- NCT02542605
- Testing
- Erenumab, PACAP-38 Challenge Agent
- Where
- 3 sites in United States, Belgium and 1 more
- Volunteers
- 35 people
- Sponsor
- Amgen
Asthma Patients
Investigation of Efficacy, Safety and Tolerability of Once and Twice Daily Doses of AZD1981 in Asthmatic Patients
The study will assess the efficacy, safety and tolerability of AZD1981 compared to non-active compound in asthmatic patients.
- Trial name
- Sweapea (NCT01197794)
- Testing
- AZD1981
- Where
- 105 sites in United States, Argentina and 8 more
- Volunteers
- 1,144 people
- Sponsor
- AstraZeneca
Type I Diabetes Mellitus
Clinical Trial of Efficacy and Safety of Subetta in the Combined Treatment of Patients With Type I Diabetes Mellitus
The purpose of this study is: to assess clinical efficacy of Subetta in the combined treatment of type I diabetes mellitus; to assess safety of Subetta in the combined treatment of type I diabetes mellitus.
- Trial name
- NCT01868594
- Testing
- Subetta
- Where
- 15 sites in Russia
- Volunteers
- 200 people
- Sponsor
- Materia Medica Holding
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.